Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment

Toxicology

Volumn 331, Issue , 2015, Pages 78-99

  Sidhu, Mandeep S ^a,b   Desai, Karan P ^b   Lynch, Heather N ^c   Rhomberg, Lorenz R ^c   Beck, Barbara D ^c   Venditti, Ferdinand J ^a,b  

^a ALBANY MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c GRADIENT   (United States)

Author keywords

Arsenic; Atherosclerosis; Cardiovascular disease; Cardiovascular toxicity; Mechanism of action

Indexed keywords

ARSENIC; BIOLOGICAL MARKER; ORGANOARSENIC DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR TOXICITY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; GENETICS; HOMEOSTASIS; HUMAN; LIVER DYSFUNCTION; METHYLATION; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICITY; ANIMAL; ARSENIC POISONING; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DOSE RESPONSE; RISK FACTOR; TOXICITY TESTING;

ANIMALIA;

ANIMALS; ARSENIC POISONING; ARSENICALS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK ASSESSMENT; RISK FACTORS; TOXICITY TESTS;

EID: 84925340832     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.02.008     Document Type: Review

References (170)

1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for arsenic. Draft for Public Comment, 2007. Atlanta GA (updated 2011 March). (accessed 07.06.14.). http://www.atsdr.cdc.gov/toxprofiles/tp.asp%3Fid=22&tid=3.
2. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49(April (4)):755-765.
3. Alissa E.M., Ferns G.A. Heavy metal poisoning and cardiovascular disease. J. Toxicol. 2011, 2011. arxiv:/870125, 10.1155/2011/870125.
4. Antonelli R., Shao K., Thomas D.J., Sams R., Cowden J. AS3MT, GSTO, and PNP polymorphisms: impact on arsenic methylation and implications for disease susceptibility. Environ. Res. 2014, 132(July):156-167. Epub 2014 May 8, Review PubMed PMID: 24792412. 10.1016/j.envres.2014.03.012.
5. Anuurad E., Boffa M.B., Koschinsky M.L., Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 2006, 26(December (4)):751-772. Review PubMed PMID: 17110238.
6. Aposhian H.V., Zakharyan R.A., Avram M.D., Sampayo-Reyes A., Wollenberg M.L. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol. Appl. Pharmacol. 2004, 198(August (3)):327-335.
7. Arias I.M. The biology of hepatic endothelial cell fenestrae. Progress in Liver Diseases IX 1990, 11-26. WB Saunders, Philadelphia. F. Schaffer, H. Popper (Eds.).
8. Aylward L.L., Ramasamy S., Hays S.M., Schoeny R., Kirman C.R. Evaluation of urinary speciated arsenic in NHANES: issues in interpretation in the context of potential inorganic arsenic exposure. Regul. Toxicol. Pharmacol. 2014, 69(1):49-54. 10.1016/j.yrtph.2014.02.011.
9. Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr. Pharm. Des. 2009, 15(27):3116-3132.
10. Balakumar P., Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc. Toxicol. 2009, 9(December (4)):169-176. 10.1007/s12012-009-9050-6.
11. Barchowsky A., Dudek E.J., Treadwell M.D., Wetterhahn K.E. Arsenic induces oxidant stress and NF-κB activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 1996, 21(6):783-790.
12. Barchowsky A., Klei L.R., Dudek E.J., Swartz H.M., James P.E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 1999, 27(December (11-12)):1405-1412.
13. Berk B.C. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 2001, 81(July (3)):999-1030.
14. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ. Res. 2006, 99(September (7)):692-705.
15. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104(September (12)):1336-1342.
16. Boobis A.R., Cohen S.M., Dellarco V., McGregor D., Meek M.E., Vickers C., et al. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36(November (10)):781-792.
17. Brauer M., Brumm J., Vedal S., Petkau A.J. Exposure misclassification and threshold concentrations in time series analyses of air pollution health effects. Risk Anal. 2002, 22(December (6)):1183-1193. PubMed PMID: 12530788.
18. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol. 2013, 167(August (4)):1109-1117. 10.1016/j.ijcard.2012.09.085.
19. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001, 345(November (22)):1583-1592.
20. Brugts J.J., Yetgin T., Hoeks S.E., Gotto A.M., Shepherd J., Westendorp R.G., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338(June (30)):b2376. 10.1136/bmj.b2376.
21. Bunderson M., Brooks D.M., Walker D.L., Rosenfeld M.E., Coffin J.D., Beall H.D. Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol. Appl. Pharmacol. 2004, 201(November (1)):32-39.
22. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data 2012, Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD, U.S.
23. Carter D.E., Aposhian H.V., Gandolfi A.J. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol. Appl. Pharmacol. 2003, 193(December (3)):309-334.
24. Cathcart M.K., Folcik V.A. Lipoxygenases and atherosclerosis: protection versus pathogenesis. Free Radic. Biol. Med. 2000, 28(June (12)):1726-1734.
25. Ch'i I.C., Blackwell R.Q. A controlled retrospective study of Blackfoot disease, an endemic peripheral gangrene disease in Taiwan. Am. J. Epidemiol. 1968, 88(July (1)):7-24.
26. Chambless L.E., Folsom A.R., Sharrett A.R., Sorlie P., Couper D., Szklo M., et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J. Clin. Epidemiol. 2003, 56(September (9)):880-890.
27. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995, 25(January (1)):53-60.
28. Chen C.J., Chiou H.Y., Chiang M.H., Lin L.J., Tai T.Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler. Thromb. Vasc. Biol. 1996, 16(April (4)):504-510.
29. Chen Y.C., Lin-Shiau S.Y., Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell. Physiol. 1998, 177(November (2)):324-333.
30. Chen Y., Hakim M.E., Parvez F., Islam T., Rahman A.M., Ahsan H. Arsenic exposure from drinking-water and carotid artery intima-medial thickness in healthy young adults in Bangladesh. J. Health Popul. Nutr. 2006, 24(June (2)):253-257.
31. Chen Y., Factor-Litvak P., Howe G.R., Graziano J.H., Brandt-Rauf P., Parvez F., et al. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. Am. J. Epidemiol. 2007, 165(March (5)):541-552.
32. Chen Y., Santella R.M., Kibriya M.G., Wang Q., Kappil M., Verret W.J., et al. Association between arsenic exposure from drinking water and plasma levels of soluble cell adhesion molecules. Environ. Health Perspect. 2007, 115(October (10)):1415-1420.
33. Chen Y., Graziano J.H., Parvez F., Liu M., Slavkovich V., Kalra T., et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ 2011, 342(May (5)):d2431. 10.1136/bmj.d2431.
34. Chen Y., Wu F., Liu M., Parvez F., Slavkovich V., Eunus M., et al. A prospectivestudy of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ. Health Perspect. 2013, 121(July (7)):832-838. 10.1289/ehp.1205797.
35. Chen Y., Wu F., Parvez F., Ahmed A., Eunus M., McClintock T.R., et al. Arsenic exposure from drinking water and QT-interval prolongation: results from the Health Effects of Arsenic Longitudinal Study. Environ. Health Perspect. 2013, 121(April (4)):1-7. 10.1289/ehp.1205197.
36. Chen Y., Wu F., Graziano J.H., Parvez F., Liu M., Paul R.R., et al. Arsenic exposure from drinking water, arsenic methylation capacity, and carotidintima-media thickness in Bangladesh. Am. J. Epidemiol. 2013, 3:372-381. 10.1093/aje/kwt001.
37. Cohen S.M., Arnold L.L., Eldan M., Schoen A.S., Beck B.D. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 2006, 36:99-133.
38. Cohen S.M., Arnold L.L., Beck B.D., Lewis A.S., Eldan M. Evaluation of the carcinogenicity of inorganic arsenic. Crit. Rev. Toxicol. 2013, 9(October (9)):711-752. 10.3109/10408444.2013.827152.
39. Daemen M.J., Kooi M.E. Intraplaque hemorrhage as a stimulator of episodic growth of advanced, but nonsymptomatic atherosclerotic lesions bridging the gap. JACC Cardiovasc. Imaging 2009, 2(December (12)):1390-1392. 10.1016/j.jcmg.2009.09.009.
40. Ding K., Kullo I.J. Genome-wide association studies for atherosclerotic vasculardisease and its risk factors. Circ. Cardiovasc. Genet. 2009, 2(February):63-72. 10.1161/CIRCGENETICS.108.816751.
41. Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction. N. Engl. J. Med. 2012, 14(October (14)):1310-1320. 10.1056/NEJMoa1107477.
42. Engstrom K., Vahter N., Mlakar S.J., Concha G., Nermell B., Raqib R., Cardozo A., Broberg R. Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 2011, 119(2):182-188. 10.1289/ehp.1002471.
43. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11(1):81-128.
44. Gamble M.V., Liu X., Ahsan H., Pilsner R., Ilievski V., Slavkovich V., et al. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ. Health Perspect. 2005, 113(December (12)):1683-1688.
45. Gamble M.V., Liu X., Ahsan H., Pilsner J.R., Ilievski V., Slavkovich V., et al. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Am. J. Clin. Nutr. 2006, 84(November (5)):1093-1101.
46. Gamble M.V., Liu X., Slavkovich V., Pilsner J.R., Ilievski V., Factor-Litvak P., et al. Folic acid supplementation lowers blood arsenic. Am. J. Clin. Nutr. 2007, 86(October (4)):1202-1209.
47. Gau G.T., Wright R.S. Pathophysiology, diagnosis, and management of dyslipidemia. Curr. Probl. Cardiol. 2006, 7(July (7)):445-486.
48. Gaudio E., Nobili V., Franchitto A., Onori P., Carpino G. Nonalcoholic fatty liver disease and atherosclerosis. Intern. Emerg. Med. 2012, 7(October (Suppl. 3)):S297-S305. 10.1007/s11739-012-0826-5.
49. Gentry P.R., Clewell H.J., Greene T.B., Franzen A.C., Yager J.W. The impact of recent advances in research on arsenic cancer risk assessment. Regul. Toxicol. Pharm. 2014, 69(June (1)):91-104. Epub 2014 Feb 15, PubMed PMID: 24534001. 10.1016/j.yrtph.2014.02.006.
50. Getz G.S., Reardon C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32(May (5)):1104-1115. 10.1161/ATVBAHA.111.237693.
51. Gilbert-Diamond D., Cottingham K.L., Gruber J.F., Punshon T., Sayarath V., Gandolfi A.J., Baker E.R., Jackson B.P., Folt C.L., Karagas M.R. Rice consumption contributes to arsenic exposure in US women. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(51):20656-20660.
52. Gong G., O'Bryant S.E. Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. Environ. Res. 2012, 113(February):52-57. 10.1016/j.envres.2012.01.003.
53. Gorby M.S. Arsenic poisoning. West. J. Med. 1988, 149(September (3)):308-315.
54. Guha Mazumder D., Purkayastha I., Ghose A., Mistry G., Saha C., Nandy A.K., et al. Hypertension in chronic arsenic exposure: a case control study in West Bengal. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 2012, 47(11). 10.1080/10934529.2012.680329.
55. Guthikonda S., Haynes W.G. Homocysteine role and implications in atherosclerosis. Curr. Atheroscler. Rep. 2006, 8(March (2)):100-106.
56. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352(April (16)):1685-1695.
57. Harper K.N., Liu X., Hall M.N., Ilievski V., Oka J., Calancie L., et al. A dose-response study of arsenic exposure and markers of oxidative damage in Bangladesh. J. Occup. Environ. Med. 2014, 56(June (6)):652-658. 10.1097/JOM.166.
58. Heart Protection Study Collaborative Group MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(July (9326)):7-22.
59. Howe C.G., Niedzwiecki M.M., Hall M.N., Liu X., Ilievski V., Slavkovich V., et al. Folate and cobalamin modify associations between S-adenosylmethionine and methylated arsenic metabolites in arsenic-exposed Bangladeshi adults. J. Nutr. 2014, 144(May (5)):690-697. 10.3945/jn.113.188789.
60. Hsieh Y.C., Lien L.M., Chung W.T., Hsieh F.I., Hsieh P.F., Wu M.M., et al. Significantly increased risk of carotid atherosclerosis with arsenicexposure and polymorphisms in arsenic metabolism genes. Environ. Res. 2011, 111(August (6)):804-810. 10.1016/j.envres.2011.05.003.
61. Hsueh Y.M., Wu W.L., Huang Y.L., Chiou H.Y., Tseng C.H., Chen C.J. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 1998, 141(December (2)):249-257.
62. Hsueh Y.M., Lin P., Chen H.W., Shiue H.S., Chung C.J., Tsai C.T., et al. Genetic polymorphisms of oxidative and antioxidant enzymes andarsenic-related hypertension. J. Toxicol. Environ. Health A 2005, 68(September (17-18)):1471-1484.
63. Huang Y.K., Tseng C.H., Huang Y.L., Yang M.H., Chen C.J., Hsueh Y.M. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol. Appl. Pharmacol. 2007, 218(January (2)):135-142.
64. Huang Y., Bi Y., Xu M., Ma Z., Xu Y., Wang T., et al. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler. Thromb. Vasc. Biol. 2012, 32(September (9)). 10.1161/ATVBAHA.112.252957.
65. Insull W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med. 2009, 122(January (Suppl. 1)):S3-S14. 10.1016/j.amjmed.2008.10.013.
66. Islam K., Haque A., Karim R., Fajol A., Hossain E., Salam K.A., et al. Dose-response relationship between arsenic exposure and the serum enzymes for liver function tests in the individuals exposed to arsenic: a cross sectional study in Bangladesh. Environ. Health 2011, 10:64.
67. Islam R., Khan I., Hassan S.N., McEvoy M., D'Este C., Attia J., Peel R., Sultana M., Akter S., Milton A.H. Association between type 2 diabetes and chronic arsenic exposure in drinking water: a cross sectional study in Bangladesh. Environ. Health 2012, 11(June (7)):38. PubMed PMID: 22676249. 10.1186/1476-069X-11-38.
68. James K.A., Byers T., Hokanson J.E., Meliker J.R., Zerbe G.O., Marshall J.A. Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in colorado residents. Environ. Health Perspect. 2014, (October 28). [Epub ahead of print].
69. Jennrich P. The influence of arsenic, lead, and mercury on the development of cardiovascular diseases. ISRN Hypertens. 2013, 2013:1-15. Article ID 234034.
70. Jones R., Tellez-Plaza M., Sharrett A.R., Guallar E., Navas-Acien A. Urine arsenic and hypertension in US adults: the 2003-2008 National Health and Nutrition Examination Survey. Epidemiology 2011, 22:153-161.
71. Kadayifci A., Tan V., Ursell P.C., Merriman R.B., Bass N.M. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J. Hepatol. 2008, 49(October (4)):595-599. 10.1016/j.jhep.2008.05.024.
72. Karim M.R., Rahman M., Islam K., Mamun A.A., Hossain S., Hossain E., et al. Increases in oxidized low-density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol. Sci. 2013, 135(September (1)):17-25. 10.1093/toxsci/kft130.
73. Khoury M.J., Davis R., Gwinn M., Lindegren M.L., Yoon P. Do we need genomic research for the prevention of common diseases with environmental causes?. Am. J. Epidemiol. 2005, 161(May (9)):799-805.
74. Kim Y., Lee B.K. Association between urinary arsenic and diabetes mellitus in the Korean general population according to KNHANES 2008. Sci. Total Environ. 2011, 409(September (19)):4054-4062. Epub 2011 July 1, PubMed PMID: 21723589. 10.1016/j.scitotenv.2011.06.003.
75. Kleemann R., Verschuren L., van Erk M.J., Nikolsky Y., Cnubben N.H., Verheij E.R., et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007, 8(9):R200.
76. Kumagai Y., Pi J. Molecular basis for arsenic-induced alteration in nitricoxide production and oxidative stress: implication of endothelial dysfunction. Toxicol. Appl. Pharmacol. 2004, 198(August (3)):450-457.
77. Kurzius-Spencer M., Burgess J.L., Harris R.B., Hartz V., Roberge J., Huang S., Hsu C.H., O'Rourke M.K. Contribution of diet to aggregate arsenic exposures-an analysis across populations. J. Expo. Sci. Environ. Epidemiol. 2014, 24(2):156-162.
78. Kuvin J.T., Patel A., Sidhu M.S., Sliney K., Pandian N., Karas R. The relationship between HDL-cholesterol and peripheral vasomotor function. Am. J. Cardiol. 2003, 92(August (1)):275-279.
79. Kuvin J.T., Sidhu M.S., Sliney K., Pandian N., Karas R. The relationship between pulse pressure and peripheral arterial vasoreactivity. J. Hum. Hypertens. 2005, 19(June (6)):501-502.
80. Kwok R.K., Mendola P., Liu Z.Y., Savitz D.A., Heiss G., Ling H.L., et al. Drinking water arsenic exposure and blood pressure in healthy women of reproductive age in Inner Mongolia, China. Toxicol. Appl. Pharmacol. 2007, 222(August (3)):337-343.
81. Larsson A., Sköldenberg E., Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 2002, 5(1-2):107-110.
82. Lee P.C., Ho I.C., Lee T.C. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol. Sci. 2005, 85(May (1)):541-550.
83. Lemaire M., Lemarié C.A., Molina M.F., Schiffrin E.L., Lehoux S., Mann K.K. Exposure to moderate arsenic concentrations increases atherosclerosis in ApoE-/- mouse model. Toxicol. Sci. 2011, 122(July (1)):211-221. 10.1093/toxsci/kfr097.
84. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinkingwater arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 1999, 107(May (5)):359-365.
85. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
86. Libby P. Changing concepts of atherogenesis. J. Intern. Med. 2000, 247(March (3)):349-358.
87. Libby P. Atherosclerosis disease biology affecting the coronary vasculature. Am. J. Cardiol. 2006, 247(March (3)):3Q-9Q.
88. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(May (7347)):317-325.
89. Lilly L.S. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty 2011, Wolters Kluwer/Lippincott Williams & Wilkins, Baltimore, MD.
90. Lisabeth L.D., Ahn H.J., Chen J.J., Sealy-Jefferson S., Burke J.F., Meliker J.R. Arsenic in drinking water and stroke hospitalizations in Michigan. Stroke 2010, 41(11):2499-2504.
91. Lu M., Wang H., Li X.F., Arnold L.L., Cohen S.M., Le X.C. Binding of dimethylarsinous acid to cys-13-α of rat hemoglobin is responsible for retention of arsenic in rat blood. Chem. Res. Toxicol. 2007, 20:27-37.
92. Medrano M.A.J., Boix R., Pastor-Barriuso R., Palau M., Damián J., Ramis R., et al. Arsenic in publicwater supplies and cardiovascular mortality in Spain. Environ. Res. 2010, 110(5):448-454.
93. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., et al. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33(6):591-653.
94. Meliker J.R., Wahl R.L., Cameron L.L., Nriagu J.O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health 2007, 6:4.
95. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 14(July (15)):3893-3903.
96. Moon K., Guallar E., Navas-Acien A. Arsenic exposure and cardiovascular disease: an updated systematic review. Curr. Atheroscler. Rep. 2012, 14(December (6)):542-555. Review PubMed PMID: 22968315. 10.1007/s11883-012-0280-x.
97. Moon K.A., Guallar E., Umans J.G., Devereux R.B., Best L.G., Francesconi K.A., et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann. Intern. Med. 2013, 159(November (10)):649-659.
98. Mordukhovich I., Wright R.O., Amarasiriwardena C., Baja E., Baccarelli A., Suh H., et al. Association between low-level environmental arsenic exposure and QT interval duration in a general population study. Am. J. Epidemiol. 2009, 170(September (6)):739-746. 10.1093/aje/kwp191.
99. Moreno P.R., Purushothaman K.R., Zias E., Sanz J., Fuster V. Neovascularization in human atherosclerosis. Curr. Mol. Med. 2006, 6(August (5)):457-477. Review PubMed PMID: 16918368.
100. Mozaffarian D., Wilson P.W., Kannel W.B. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 2008, 117(June (23)):3031-3038.
101. NRC Critical Aspects of EPA's IRIS Assessment of Inorganic Arsenic: Interim Report. Committee on Inorganic Arsenic: Board on Environmental Studies and Toxicology: Division on Earth and Life Studies: National Research Council 2013, National Academies Press, Washington, D.C.
102. Nesnow S., Roop B.C., Lambert G., Kadiiska M., Mason R.P., Cullen W.R., et al. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 2002, 15(December (12)):1627-1634.
103. Ngalame N.N., Micciche A.F., Feil M.E., States J.C. Delayed temporal increase of hepatic Hsp70 in ApoE knockout mice after prenatal arsenic exposure. Toxicol. Sci. 2013, 131(January (1)):225-233. Epub 2012 September 5, PubMed PMID: 22956628. 10.1093/toxsci/kfs264.
104. Nyyssonen K., Porkkala E., Salonen R., Korpela H., Salonen J.T. Increase in oxidation resistance of atherogenic serum lipoproteins following antioxidant supplementation: a randomized double-blind placebo-controlled clinical trial. Eur. J. Clin. Nutr. 1994, 48:633-642.
105. O'Donnell C.J., Kannel W.B. Cardiovascular risks of hypertension: lessons from observational studies. J. Hypertens. 1998, 16(October (Suppl. 6)):S3-S7.
106. Okumura K., Tsukamoto H. Folate in smokers. Clin. Chim. Acta 2011, 412(March (7-8)):521-526.
107. Osorio-Yáñez C., Ayllon-Vergara J.C., Aguilar-Madrid G., Arreola-Mendoza L., Hernández-Castellanos E., Barrera-Hernández A., et al. Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environ. Health Perspect. 2013, 121(September (9)):1090-1096. 10.1289/ehp.1205994.
108. Petito Boyce C., Lewis A.S., Sax S.N., Eldan M., Cohen S.M., Beck B.D. Probabilistic analysis of human health risks associated with background concentrations of inorganic arsenic: use of a margin of exposure approach. Hum. Ecol. Risk Assess. 2008, 14:1159-1201.
109. Pilsner J.R., Liu X., Ahsan H., Ilievski V., Slavkovich V., Levy D., Factor-Litvak P., Graziano J.H., Gamble M.V. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. Environ. Health Perspect. 2009, 117(Feburary (2)):254-260. Epub 2008 September 26, PubMed PMID: 19270796. 10.1289/ehp.11872.
110. Pober J.S., Min W., Bradley J.R. Mechanisms of endothelial dysfunction, injury, and death. Annu. Rev. Pathol. 2009, 4:71-95. 10.1146/annurev.pathol.4.110807.092155.
111. Powell C.L., Kosyk O., Ross P.K., Schoonhoven R., Boysen G., Swenberg J.A., et al. Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in ratliver. Toxicol. Sci. 2006, 93(September (1)):213-222.
112. Rahman M., Tondel M., Ahmad S.A., Chowdhury I.A., Faruquee M.H., Axelson O. Hypertension and arsenic exposure in Bangladesh. Hypertension 1999, 33(January (1)):74-78.
113. Rapant S., Cvecková V., Dietzová Z., Khun M., Letkovicová M. Medical geochemistry research in Spissko-Gemerské rudohorie Mts. Slovakia Environ. Geochem. Health 2009, 31(1):11-25.
114. Rhomberg L.R., Chandalia J.K., Long C.M., Goodman J.E. Measurement error inenvironmental epidemiology and the shape of exposure-response curves. Crit. Rev. Toxicol. 2011, 41(September (8)):651-671. 10.3109/10408444.2011.563420.
115. Rhomberg L.R., Goodman J.E., Haber L.T., Dourson M., Andersen M.E., Klaunig J.E., et al. Linear low-dose extrapolation for non cancer health effects is the exception, not the rule. Crit. Rev. Toxicol. 2011, 41(January (1)):1-19. 10.3109/10408444.2010.536524.
116. Ridker P., Libby P., et al. Risk factors for atherothrombotic disease. Braunwald's Heart Disease 2012, Elsevier Saunders, Philadelphia. ninth ed. R. Bonow (Ed.).
117. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351(Janurary (9096)):88-92.
118. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342(March (12)):836-843.
119. Rosenberg H.G. Systemic arterial disease and chronic arsenicism in infants. Arch. Pathol. 1974, 97(June (6)):360-365.
120. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340(January (2)):115-126.
121. Rossman T. Arsenic. Environmental and Occupational Medicine 2007, 1006-1017. Lippincott Williams & Wilkins, Hagerstown, MD. fourth ed. W. Rom, S. Markowitz (Eds.).
122. Ruiz-Navarro M.L., Navarro-Alarcón M., Lopez González-de la Serrana H., Pérez-Valero V., López-Martinez M.C. Urine arsenic concentrations in healthy adults as indicators of environmental contamination: relation with some pathologies. Sci. Total Environ. 1998, 216(1-2):55-61.
123. Salonen J.T., Salonen R., Seppänen K., Rinta-Kiikka S., Kuukka M., Korpela H., et al. Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blindtrial in men with low antioxidant status. Am. J. Clin. Nutr. 1991, 53(May (5)):1222-1229.
124. Simeonova P.P., Luster M.I. Arsenic and atherosclerosis. Toxicol. Appl. Pharmacol. 2004, 198(August (3)):444-449. Review PubMed PMID: 15276425.
125. Simeonova P.P., Hulderman T., Harki D., Luster M.I. Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ. Health Perspect. 2003, 111(November (14)):1744-1748.
126. Sohel N., Persson L.A., Rahman M., Streatfield P.K., Yunus M., Ekström E.C., et al. Arsenic in drinking water and adult mortality: a population-based cohort study in rural Bangladesh. Epidemiology 2009, 20(November (20)):824-830. 10.1097/EDE.0b013e3181bb56ec.
127. Soucy N.V., Mayka D., Klei L.R., Nemec A.A., Bauer J.A., Barchowsky A. Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. Cardiovasc. Toxicol. 2005, 5(1):29-41.
128. Spallholz J.E., Mallory Boylan L., Rhaman M.M. Environmental hypothesis: is poordietary selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India?. Sci. Total Environ. 2004, 323(May (1-3)):21-32.
129. Srivastava S., D'Souza S.E., Sen U., States J.C. In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice. Reprod. Toxicol. 2007, 23(April-May (3)):449-456.
130. Srivastava S., Vladykovskaya E.N., Haberzettl P., Sithu S.D., D'Souza S.E., States J.C. Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicol. Appl. Pharmacol. 2009, 241(November (1)):90-100. 10.1016/j.taap.2009.08.004.
131. Srivastava D., Subramanian R.B., Madamwar D., Flora S.J. Protective effects of selenium, calcium, and magnesium against arsenic-induced oxidative stress in malerats. Arch. Ind. Hyg. Toxicol. 2010, 61(June (2)):153-159.
132. Stýblo M., Drobná Z., Jaspers I., Lin S., Thomas D.J. The role of biomethylation intoxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 2002, 110(October (Suppl. 5)):767-771.
133. States J.C., Srivastava S., Chen Y., Barchowsky A. Arsenic and cardiovascular disease. Toxicol. Sci. 2009, 107:312-323.
134. States J.C., Barchowsky A., Cartwright I.L., Reichard J.F., Futscher B.W., Lantz R.C. Arsenic toxicology: translating between experimental models and human pathology. Environ. Health Perspect. 2011, 119(October (10)):1356-1363.
135. States J.C., Singh A.V., Knudsen T.B., Rouchka E.C., Ngalame N.O., Arteel G.E., Piao Y., Ko M.S.H. Prenatal arsenic exposure alters gene expression in the adult liver to a proinflammatory state contributing to accelerated atherosclerosis. PLoS One 2012, 7(6):e38713. Epub 2012 June 15, PubMedPMID: 22719926. 10.1371/journal.pone.0038713.
136. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320(April (14)):915-924.
137. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(June (Suppl. 2)):S1-S45. 10.1161/01.cir.0000437738.63853.7a.
138. Straub A.C., Stolz D.B., Vin H., Ross M.A., Soucy N.V., Klei L.R., et al. Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol. Appl. Pharmacol. 2007, 222(August (3)):327-336.
139. Straub A.C., Stolz D.B., Ross M.A., Hernández-Zavala A., Soucy N.V., Klei L.R., et al. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology 2007, 45(January (1)):205-212.
140. Straub A.C., Clark K.A., Ross M.A., Chandra A.G., Li S., Gao X., et al. Arsenic-stimulated liver sinusoidal capillarization in micerequires NADPH oxidase-generated superoxide. J. Clin. Invest. 2008, 118(December (12)):3980-3989. 10.1172/JCI35092.
141. Suzuki S., Arnold L.L., Ohnishi T., Cohen S.M. Effects of inorganic arsenic on the rat and mouse urinary bladder. Toxicol. Sci. 2008, 106:350-363.
142. Tan M., Schmidt R.H., Beier J.I., Watson W.H., Zhong H., States J.C., Arteel G.E. Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. Toxicol. Appl. Pharmacol. 2011, 257(December (3)):356-364. Epub 2011 September 29, PubMed PMID: 21983427. 10.1016/j.taap.2011.09.019.
143. Thomas D.J., Li J., Waters S.B., Xing W., Adair B.M., Drobna Z., Devesa V., Styblo M. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 2007, 232(1):3-13. Review PubMed PMID: 17202581.
144. Tseng C.H., Tai T.Y., Chong C.K., Tseng C.P., Lai M.S., Lin B.J., et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ. Health Perspect. 2000, 108(September (9)):847-851.
145. Tseng C.H. Blackfoot disease and arsenic: a never-ending story. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2005, 23(1):55-74. Review PubMed PMID: 16291522.
146. Tsuji J.S., Perez V., Garry M.R., Alexander D.D. Association of low-level arsenicexposure in drinking water with cardiovascular disease: a systematic review andrisk assessment. Toxicology 2014, 323(September):78-94. 10.1016/j.tox.2014.06.008.
147. Tsuji J.S., Alexander D.D., Perez V., Mink P.J. Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses. Toxicology 2014, 317(March):17-30. 10.1016/j.tox.2014.01.004.
148. National Center for Environmental Assessment (NCEA), April 2014. Draft Development Materials for the Integrated Risk Information System (IRIS) Toxicological Review of Inorganic Arsenic [CASRN 7440-38-2]. EPA/630/R-14/101, pp. 731. (accessed 28.04.14.). http://www.epa.gov/iris/publicmeeting/iris_bimonthly-jun2014.
149. US Geological Survey (USGS), Focazio, M.J., Welch, A.H., Watkins, S.A., Helsel, D.R., Horn, M.A., 2000. A Retrospective Analysis on the Occurrence of Arsenic in Ground-Water Resources of the United States and Limitations in Drinking-Water-Supply Characterizations. USGS Water-Resources Investigations Report 99-4279, pp. 27.
150. US Geological Survey (USGS), July 2003. Arsenic Concentrations in Private Bedrock Wells in Southeastern New Hampshire. USGS Fact Sheet 051-03, 6p. 2014. , [214-9977], (accessed 19.12.14.). http://pubs.usgs.gov/fs/fs-051-03/pdf/fs-051-03.pdf.
151. University of Arizona, College of Agriculture and Life Sciences, Arizona Cooperative Extension, May 2008. Arsenic in Arizona Ground Water: Source and Transport Characteristics. AZ1453, pp. 4. (accessed 19.12.14.). http://www.prescott-az.gov/_d/arsenicarizonagroundwater-
152. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181-182(December):211-217.
153. Vardavas C.I., Linardakis M.K., Hatzis C.M., Malliaraki N., Saris W.H., Kafatos A.G. Smoking status in relation to serum folate and dietary vitamin intake. Tob. Induc. Dis. 2008, 4(September):8.
154. Wade T.J., Xia Y., Wu K., Li Y., Ning Z., Le X.C., et al. Increased mortality associated with well-water arsenic exposure in Inner Mongolia, China. Int. J. Environ. Res. Public Health 2009, 6(March (3)):1107-1123. 10.3390/ijerph6031107.
155. Wang Z., Dey S., Rosen B.P., Rossman T.G. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol. Appl. Pharmacol. 1996, 137(March (1)):112-119.
156. Wang C.H., Jeng J.S., Yip P.K., Chen C.L., Hsu L.I., Hsueh Y.M., et al. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 2002, 105(April (15)):1804-1809.
157. Wang Y.H., Wu M.M., Hong C.T., Lien L.M., Hsieh Y.C., Tseng H.P., et al. Effects of arsenic exposure and genetic polymorphisms of p53, glutathione S-transferase M1, T1, and P1 on the risk of carotid atherosclerosis in Taiwan. Atherosclerosis 2007, 192(June (2)):305-312.
158. Wang C.H., Chen C.L., Hsiao C.K., Chiang F.T., Hsu L.I., Chiou H.Y., et al. Increased risk of QT prolongation associated with atherosclerotic diseases in arseniasis-endemic area in southwestern coast of Taiwan. Toxicol. Appl. Pharmacol. 2009, 239(September (3)):320-324. 10.1016/j.taap.2009.06.017.
159. Warren A., Cogger V.C., Arias I.M., McCuskey R.S., Le Couteur D.G. Liver sinusoidal endothelial fenestrations in caveolin-1 knockout mice. Microcirculation 2010, 17(January (1)):32-38. 10.1111/j.1549-8719.2009.00004.
160. Williams T.M., Lisanti M.P. The Caveolin genes: from cell biology to medicine. Annu. Med. 2004, 36(8):584-595.
161. Wisse E., De Zanger R.B., Charels K., Van Der Smissen P., McCuskey R.S. The liversieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985, 5(July-August (4)):683-692.
162. Wu M.M., Chiou H.Y., Ho I.C., Chen C.J., Lee T.C. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ. Health Perspect. 2003, 111(August (11)):1429-1438.
163. Wu M.M., Chiou H.Y., Chen C.L., Wang Y.H., Hsieh Y.C., Lien L.M., et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol. Appl. Pharmacol. 2010, 248(November (3)):226-233. 10.1016/j.taap.2010.08.005.
164. Wu F., Molinaro P., Chen Y. Arsenic exposure and subclinical endpoints of cardiovascular diseases. Curr. Environ. Health Rep. 2014, 1(June (2)):148-162.
165. Yildiz A., Karaca M., Biceroglu S., Nalbantcilar M.T., Coskun U., Arik F., et al. Effect of chronic arsenic exposure from drinking waters onthe QT interval and transmural dispersion of repolarization. J. Int. Med. Res. 2008, 36(May-June (3)):471-478.
166. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (+3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol. Appl. Pharmacol. 2010, 246(July (1-2)):1-7. Epub 2010 April 25, PubMed PMID: 20423714. 10.1016/j.taap.2010.04.013.
167. Yokohira M., Arnold L.L., Pennington K.L., Suzuki S., Kakiuchi-Kiyota S., Herbin-Davis K., Thomas D.J., Cohen S.M. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol. Sci. 2011, 121(June (2)):257-266. Epub 2011 March 7, PubMed PMID: 21385732. 10.1093/toxsci/kfr051.
168. Zadelaar S., Kleemann R., Verschuren L., de Vries-Van der Weij J., van der Hoorn J., Princen H.M., Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 2007, 27(August (8)):1706-1721. Epub 2007 May 31, Review PubMed PMID: 17541027.
169. Zakharyan R.A., Aposhian H.V. Arsenite methylation by methyl vitamin B12 and glutathione does not require an enzyme. Toxicol. Appl. Pharmacol. 1999, 154(Feburary (3)):287-291.
170. Zierold K.M., Knobeloch L., Anderson H. Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water. Am. J. Public Health 2004, 94(November (11)):1936-1937.